L'Oreal shares slide as cosmetics giant cites weakness in China
By Steve Goldstein
L'Oreal shares fell as much as 8% on Friday as the cosmetics giant said it's continuing to see pressure from mainland China and what it called the reset in travel spending.
The maker of its namesake brand (FR:OR) as well as Garnier and Lancome products said fourth-quarter comparable sales grew 6.9%, after 11% sales growth for the year. Analysts polled by Visible Alpha had expected 11.6% comparable sales growth for the year.
Its annnual profit rose 8% to EUR6.18 billion ($6.66 billion), as sales rose to EUR41.18 billion from EUR38.26 billion. Analysts had expected a profit of EUR6.25 billion on sales of EUR41.49 billion.
Its outlook was vague, as L'Oreal said it remains optimistic on the outlook for the beauty market and its ability to outperform it.
JPMorgan kept a neutral rating on the company, noting it traded on 33 times estimated 2025 earnings excluding its stake in Sanofi.
-Steve Goldstein
This content was created by MarketWatch, which is operated by Dow Jones & Co. MarketWatch is published independently from Dow Jones Newswires and The Wall Street Journal.
(END) Dow Jones Newswires
02-09-24 0459ET
Copyright (c) 2024 Dow Jones & Company, Inc.-
What’s the Difference Between the CPI and PCE Indexes?
-
Powell Unfazed By Sticky Inflation, but Rate Cuts Are Far Off
-
After Earnings, Is Microsoft Stock a Buy, a Sell, or Fairly Valued?
-
Best- and Worst-Performing Stocks of April 2024
-
Magnificent 7 Stocks Earnings Updates: AI Remains the Focus
-
Small-Cap and Value Stocks Are Undervalued
-
Why We Expect the Job Market’s Slowdown to Renew in 2024
-
5 Undervalued Stocks to Buy to Play a Little Defense
-
10 Top-Performing Dividend Stocks of the Month
-
Marathon Petroleum Earnings: No Change to Competitive Position, but Shares Look Expensive
-
Charlie Munger and How Not to Invest
-
Look Inside Berkshire Hathaway’s Portfolio Before Its Annual Meeting
-
After Earnings, Is AT&T Stock a Buy, a Sell, or Fairly Valued?
-
Mastercard Earnings: A Stable Environment Highlights the Firm’s Strengths
-
Pfizer Earnings: Solid Results Supported by Steady Tracking Toward $4 Billion In Cost Cuts
-
Starbucks Earnings: Not a Lot to Like About Results as Global Traffic Sputters